Author + information
- Received May 13, 2009
- Revision received July 1, 2009
- Accepted July 6, 2009
- Published online October 6, 2009.
- Oliver Bruder, MD*,* (, )
- Steffen Schneider, PhD†,
- Detlef Nothnagel, MD‡,
- Thorsten Dill, MD§,
- Vinzenz Hombach, MD∥,
- Jeanette Schulz-Menger, MD¶,
- Eike Nagel, MD#,
- Massimo Lombardi, MD**,
- Albert C. van Rossum, MD††,
- Anja Wagner, MD‡‡,
- Juerg Schwitter, MD§§,
- Jochen Senges, MD†,
- Georg V. Sabin, MD*,
- Udo Sechtem, MD∥∥ and
- Heiko Mahrholdt, MD∥∥
- ↵*Reprint requests and correspondence:
Dr. Oliver Bruder, Elisabeth Hospital, Klara-Kopp-Weg 1, 45138 Essen, Germany
Objectives During its German pilot phase, the EuroCMR (European Cardiovascular Magnetic Resonance) registry sought to evaluate indications, image quality, safety, and impact on patient management of routine CMR.
Background CMR has a broad range of applications and is increasingly used in clinical practice.
Methods This was a multicenter registry with consecutive enrollment of patients in 20 German centers.
Results A total of 11,040 consecutive patients were enrolled. Eighty-eight percent of patients received gadolinium-based contrast agents. Twenty-one percent underwent adenosine perfusion, and 11% high-dose dobutamine-stress CMR. The most important indications were workup of myocarditis/cardiomyopathies (32%), risk stratification in suspected coronary artery disease/ischemia (31%), as well as assessment of viability (15%). Image quality was good in 90.1%, moderate in 8.1%, and inadequate in 1.8% of cases. Severe complications occurred in 0.05%, and were all associated with stress testing. No patient died during or due to CMR. In nearly two-thirds of patients, CMR findings impacted patient management. Importantly, in 16% of cases the final diagnosis based on CMR was different from the diagnosis before CMR, leading to a complete change in management. In more than 86% of cases, CMR was capable of satisfying all imaging needs so that no further imaging was required.
Conclusions CMR is frequently performed in clinical practice in many participating centers. The most important indications are workup of myocarditis/cardiomyopathies, risk stratification in suspected coronary artery disease/ischemia, and assessment of viability. CMR imaging as used in the centers of the pilot registry is a safe procedure, has diagnostic image quality in 98% of cases, and its results have strong impact on patient management.
The EuroCMR Registry is supported by unrestricted educational grants from Medtronic Inc., Minneapolis, Minnesota; Novartis International AG, Basel, Switzerland; Servier Societe, Neuilly-sur-Seine, France; and Siemens Healthcare, Erlangen, Germany. Importantly, industry sponsoring was exclusively used for registry data management and analysis. All CMR scans reported in this registry were clinically indicated according to the actual appropriateness criteria, and thus completely funded by the regular German health care providers.
- Received May 13, 2009.
- Revision received July 1, 2009.
- Accepted July 6, 2009.
- American College of Cardiology Foundation